---
title: "Kalaris Therapeutics (KLRS.US) — 财务报表"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/KLRS.US/norm.md"
symbol: "KLRS.US"
name: "Kalaris Therapeutics"
parent: "https://longbridge.com/zh-CN/quote/KLRS.US.md"
datetime: "2026-03-04T14:32:07.599Z"
locales:
  - [en](https://longbridge.com/en/quote/KLRS.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KLRS.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KLRS.US/norm.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/KLRS.US/norm.md) | [繁體中文](https://longbridge.com/zh-HK/quote/KLRS.US/norm.md)


# Kalaris Therapeutics (KLRS.US) — 财务报表

## 利润表 (USD)

| 指标 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
| --- | --- | --- | --- | --- | --- |
| 每股收益 | -0.6360 | -0.6069 | -2.52 | -3.28 | -28.16 |
| ROE | -100.18% | -77.61% | 249.12% | - | - |
| 营业收入 | - | - | - | - | - |
| 净利润 | -11.89M | -11.35M | -10.20M | -22.03M | -38.08M |
| 营业利润 | -12.74M | -12.26M | -10.35M | -7.13M | -37.85M |
| 毛利率 | - | - | - | - | - |
| 净利率 | - | - | - | - | - |
| 利润含金量 | - | - | - | - | - |

## 资产负债表 (USD)

| 指标 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
| --- | --- | --- | --- | --- | --- |
| 资产与负债 | 81.17M | 92.84M | 103.09M | 6.16M | 2.46M |
| 权益乘数 | 1.94 | 1.75 | 1.61 | -0.1217 | -0.0567 |
| 每股净资产 | 2.24 | 2.84 | 3.42 | -14.36 | -13.32 |
| 资产周转率 | - | - | - | - | - |
| 现金及短投 | 77.00M | 88.43M | 100.97M | 1.64M | 1.91M |
| 存货与应收 | - | - | - | - | - |
| 长期投资 | 1.52M | - | - | - | - |
| 净债务 | -75.45M | -88.43M | -100.97M | 18.27M | 7.34M |

## 现金流量表 (USD)

| 指标 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
| --- | --- | --- | --- | --- | --- |
| 经营现金流 | -11.33M | -12.54M | -7.44M | -7.85M | -4.33M |
| 投资现金流 | -34.71M | - | - | - | - |
| 融资现金流 | 0.0000 | 0.0000 | 107.27M | 7.58M | 1000.00 |
| 自由现金流 | -7.43M | -8.57M | -4.00M | - | - |
| 现金流充裕率 | -6192.90% | - | - | - | - |
| 举债与偿债 | 0.0000 | 0.0000 | 7.50M | 9.97M | 0.0000 |
| 资本支出 | -183000.00 | - | - | - | - |